Shelagh Glaser, CFO of Synopsys, sells $3.55m in stock

Synopsys CFO Shelagh Glaser sold 7,310 shares for $3.55 million under a pre-arranged trading plan and exercised options to acquire an equal number of shares for $2.56 million. Concurrently, Synopsys suspended its Q3 and FY25 financial guidance due to new export restrictions related to China, despite exceeding Q2 estimates with adjusted EPS of $3.67 and revenue of $1.604 billion; analysts at Stifel and KeyBanc maintain Buy/Overweight ratings with price targets of $550 and $575 respectively, anticipating growth outside of China, while BofA Securities lifted its price target to $575, also maintaining a Buy rating.

Analysis

Synopsys Inc. (SNPS) Chief Financial Officer, Shelagh Glaser, executed significant stock transactions on June 6, 2025, selling 7,310 shares at an average price of $485.72 for approximately $3.55 million under a pre-arranged Rule 10b5-1 trading plan adopted January 13, 2025. Concurrently, Glaser exercised options to acquire 7,310 shares at exercise prices between $348.17 and $354.45, totaling roughly $2.56 million, resulting in a direct holding of 15,291 shares post-transaction. The company, with a market capitalization of $77.5 billion and robust gross profit margins of 81%, trades at a high P/E ratio of 57. Despite its strong financial health, indicated by an InvestingPro "GOOD" rating and a current ratio of 7.02, Synopsys has suspended its Q3 and full-year 2025 financial guidance due to new export restrictions impacting China. This suspension followed a strong Q2 performance where adjusted EPS of $3.67 surpassed estimates of $3.39, and revenue reached $1.604 billion, slightly above expectations. Prior to the suspension, Synopsys had projected Q3 revenue between $1.755 billion and $1.785 billion and reaffirmed full-year revenue guidance of $6.745 billion to $6.805 billion. Analyst sentiment remains largely positive; Stifel maintains a Buy rating with a $550 price target, KeyBanc reiterated an Overweight rating with a $575 target, and BofA Securities raised its target to $575 with a Buy rating, all acknowledging China-related risks but expressing confidence in growth from other regions and the core business. The acquisition of Ansys (ANSS) is anticipated to close by mid-2025, though discussions in China are ongoing.

Key Decisions for Investors

• Investors should weigh Synopsys's strong underlying financial health, impressive gross margins, and positive analyst ratings against the significant uncertainty introduced by the suspension of financial guidance due to China export restrictions and its high P/E ratio of 57.
• Carefully monitor developments related to the China export restrictions and their quantifiable impact on future revenue and earnings, as this is a primary risk factor overshadowing the company's near-term outlook.
• Track the progress of the Ansys acquisition, particularly regulatory approvals in China, as its successful completion by mid-2025 could be a significant catalyst, though delays or adverse conditions could introduce further volatility.
• Note that while the CFO's recent stock sale was executed under a pre-arranged 10b5-1 plan, which can mitigate concerns about negative insider sentiment, the simultaneous guidance suspension warrants a cautious approach to new investments or position increases until more clarity emerges on the China situation.